For the full year 2016, surgery volume rose 6.6 percent over the 2015 total.
Conference drew 7 thousand ophthalmologists to colorful Jaipur, India.
Company says its adjustable IOL will improve refractive precision.
The move follows a Feb. 15 ruling in a US patent dispute that bolstered Editas’ position in the race to develop CRISPR.
Tom Frinzi will continue to lead J&J Vision’s surgical division in Santa Ana, California.
Subset of patients experienced average increase in IOP from 18 mmHg to 33 mmHg at one week.
Aier is the largest eye hospital chain in China, operating 100 free-standing eye hospitals.
The competition is designed to fund a project that makes measurable progress toward solving a significant global problem.
Thirty US glaucoma specialists are now using the gel stent in advanced glaucoma patients.
Worldwide, SMILE has been performed more than 700 thousand times since its introduction in 2011, the company says.
Valeant expects 5 to 7 percent growth for its eye care segment in 2017.
The hedge fund manager will not stand for re-election on Valeant's board.
The company credits marketing program with raising awareness of disease, drawing new patients.
This month's roundup covers Glaukos, Alimera Sciences, Aerie Pharmaceuticals, Second Sight, TearLab, and Ophthotech.
Eyegate received an upfront cash payment; the amount was not disclosed.
The segment is expected to total more than $1.9 billion in 2017.
Axitinib targets VEGF and PDGF receptors and was the firm's lead candidate for wet AMD.
In 2016, the firm closed a public offering that raised nearly $7.8 million.
Legislation receives support from optometrists and Opternative.
Customers will no longer need specific patient information to order.
You are not currently logged in.
©2017 Market Scope
Lost your Password